NCT03270969View on ClinicalTrials.gov

A Pharmacokinetic Evaluation of Tenofovir/Emtricitabine as HIV Pre-Exposure Prophylaxis in Transgender Women

PHASE1CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

January 5, 2018

Primary Completion Date

September 10, 2018

Study Completion Date

September 10, 2018

Conditions
HIV Prevention
Interventions
DRUG

Tenofovir Disoproxil Fumarate/Emtricitabine

Participants will receive daily TDF/FTC for 14 days

Trial Locations (1)

68198

University of Nebraska Medical Center, Omaha

All Listed Sponsors
lead

University of Nebraska

OTHER

NCT03270969 - A Pharmacokinetic Evaluation of Tenofovir/Emtricitabine as HIV Pre-Exposure Prophylaxis in Transgender Women | Biotech Hunter | Biotech Hunter